374 related articles for article (PubMed ID: 8549017)
1. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of alpha-glucosidase inhibition.
Bischoff H
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():3-10. PubMed ID: 8001624
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
4. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
5. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
7. alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.
Casirola DM; Ferraris RP
Metabolism; 2006 Jun; 55(6):832-41. PubMed ID: 16713445
[TBL] [Abstract][Full Text] [Related]
8. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
9. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
10. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
11. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
12. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
13. Postprandial serum lipids and tissue lipoprotein lipase are acutely altered in rats by the alpha-glucosidase inhibitor acarbose.
Picard F; Deshaies Y
Horm Metab Res; 1996 Aug; 28(8):377-80. PubMed ID: 8886823
[TBL] [Abstract][Full Text] [Related]
14. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
15. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
17. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
18. Acarbose reduces blood pressure in sucrose-induced hypertension in rats.
Madar Z; Melamed EC; Zimlichman R
Isr J Med Sci; 1997 Mar; 33(3):153-9. PubMed ID: 9313782
[TBL] [Abstract][Full Text] [Related]
19. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
20. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
Schwartzkopff W; Calder D
Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
[No Abstract] [Full Text] [Related]
[Next] [New Search]